La vendita allo scoperto per Rockwell Medical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Rockwell Medical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Rockwell Medical (NASDAQ:RMTI) Azioni, Report sulle vendite allo scoperto

Rockwell Medical

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.

Rockwell Medical Inc

DaVita, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>) has witnessed strong momentum year to date, with its shares up 47.3% compared with the&nbsp;industry&#39;s&nbsp;growth of 14.8%. The S&amp;P 500 composite has risen 19.5% in the same period.
DaVita,&nbsp;carrying a Zacks Rank #2 (Buy) at present, is witnessing an upward trend in its stock price, prompted by the company&#39;s business model. The optimism, led by a solid second-quarter 2024 performance and the acquisition of dialysis centers, is expected to contribute further.
DaVita is a leading provider of dialysis services in the United States to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services, primarily in dialysis centers and contracted hospitals across the country. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/39/80935.jpg?v=255633029" />
Image Source: Zacks Investment Research
<h2>Catalysts Driving DaVita&#39;s Growth</h2>
The rally in the company&#39;s share price can be attributed to the strength of its dialysis and related lab services. The optimism led by a solid second-quarter 2024 performance and robust business potential are expected to contribute further.
DaVita is experiencing significant growth driven by its patient-centric care approach, leveraging its kidney care services platform to offer a wide range of treatment models and modalities. The increasing prevalence of value-based partnerships in kidney health enables nephrologists, physicians, and transplant programs to collaborate more effectively, enhancing the understanding of individual patient needs and facilitating improved care coordination and early interventions.
A key element of DaVita&#39;s growth strategy is the acquisition of dialysis centers and related businesses, as evident from the recent extension of its pilot phase for a supply and collaboration agreement with Nuwellis. Upon completion of this phase, which ends on Aug. 31, 2024, DaVita may extend the agreement for the ongoing provision of inpatient and outpatient ultrafiltration services for up to 10 years.
The company&#39;s global market share is also on the rise, with recent agreements to expand operations into Brazil, Colombia, Chile and Ecuador.
In the second quarter of 2024, DaVita reported results that exceeded expectations, showcasing a positive trend in both revenue streams and patient services. The sequential increase in daily United States dialysis treatments and the opening of new centers, along with acquisitions overseas, indicates a strong growth trajectory.
Furthermore, DaVita has raised its earnings projections for fiscal 2024, now forecasting adjusted EPS in the range of $9.25 to $10.05, up from the prior range of $9 to $9.80, which is likely to attract further interest from investors.
<h2>Risk Factor</h2>
DaVita faces a risk of reduced profitability if patients shift from commercial insurance to government programs, as government reimbursement rates are significantly lower. This shift could be triggered by rising unemployment, impacting DaVita&#39;s revenues and profit margins.
<h2>A Look at Estimates</h2>
The Zacks Consensus Estimate for DaVita&#39;s 2024 and 2025 bottom line projects an 18% and 14.4% year-over-year improvement, respectively, to earnings of $9.99 and $11.42 per share.
In the past 30 days, the Zacks Consensus Estimate for the company&#39;s 2024 earnings has remained constant at $9.99 per share.
Revenues for 2024 and 2025 are anticipated to rise 5.4% and 4%, respectively, to $12.8 billion and $13.3 billion on a year-over-year basis.
<div class="chart_embed">
<h3>DaVita Inc. Price</h3>
<img alt="DaVita Inc. Price" src="https://staticx-tuner.zacks.com/images/charts/2b/1728478167.png" style="height:251px; width:544px" title="" />
DaVita Inc. price | DaVita Inc. Quote
</div>
<h2>Other Key Picks</h2>
Some other top-ranked stocks in the broader medical space are Rockwell Medical (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmti#NASDAQ">RMTI</a>), Quest Diagnostics&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dgx#NYSE">DGX</a>)&nbsp;and RadNet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>). While Rockwell Medical carries a Zacks Rank #1 (Strong Buy), Quest Diagnostics&nbsp;and RadNet carry a Zacks Rank #2 each at present.
Rockwell Medical&nbsp;earnings surpassed estimates in each of the trailing four quarters, with the average being 87.9%.
RMTI&#39;s shares have gained 79.7% compared with the industry&#39;s 10.7% growth year to date.
Quest Diagnostics&nbsp;has an estimated long-term growth rate of 6.8%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.3%.
Quest Diagnostics&nbsp;has gained 7.9% compared with the industry&#39;s 14.9% growth year to date.
RadNet&#39;s&nbsp;earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 98.2%.
RDNT&#39;s shares have gained 93.7% year to date compared with the industry&#39;s&nbsp;14.8% growth.
<a href="https://www.zacks.com/stock/news/2348406/davita-stock-gains-47-3-year-to-date-what-s-behind-the-rally?cid=CS-BENZ-FT-analyst_blog|price_surge_/_plunge-2348406">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

Mid Cap

News

Penny Stocks

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

RDNT

RMTI

DaVita Stock Gains 47.3% Year to Date: What's Behind the Rally?

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $9 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $9 Price Target

WIIM

Rockwell Medical shares are trading higher after the company announced it secured a major deal to supply dialysis products for at-home and acute care.

Rockwell Medical, Inc. (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced a product purchase agreement with the leading at-home and acute care dialysis provider in the United States (the "Customer"). Under the terms of the agreement, Rockwell Medical will supply the Customer with the Company's liquid acid RenalPure&#xAE; and liquid bicarbonate SteriLyte&#xAE;, both of which will be packaged in either the Company's four-per-case packaging for larger dialysis settings or two-per-case packaging for smaller acute care and at-home care settings.

Rockwell Medical Secures Major Deal to Supply Dialysis Products for At-Home and Acute Care

Rockwell Medical shares are trading higher after the company announced a distribution agreement with Nipro Medical.

The agreement will remain in effect for two years with the option to extend the agreement for an additional one-year period and includes product purchasing minimums of $5.0 million for the first year and incremental increases each subsequent year.&nbsp;

Contracts

Rockwell Medical Announced A Distribution Agreement With Nipro Medical, To Supply Liquid And Dry Acid And Bicarbonate Hemodialysis Concentrates, As Well As Its Dry Acid Concentrates Mixer, For Which Nipro Has The Right To Distribute Rockwell's Products Globally, Excluding US

Rockwell Medical shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY24 revenue guidance above estimates.

GUIDANCE
Rockwell Medical updates its 2024 guidance as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Updated&nbsp; 2024 Guidance&nbsp; (As of August 8, 2024)</td>
<td colspan="1" rowspan="1">Updated&nbsp; 2024 Guidance&nbsp; (As of May 14, 2024)</td>
<td colspan="1" rowspan="1">Original&nbsp; 2024 Guidance&nbsp; (As of March 21, 2024)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net (Product) Sales</td>
<td colspan="1" rowspan="1">$95.0M to $98.0M</td>
<td colspan="1" rowspan="1">$90.0M to $94.0M</td>
<td colspan="1" rowspan="1">$84.0M to $88.0M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Profit</td>
<td colspan="1" rowspan="1">$14.0M to $16.0M</td>
<td colspan="1" rowspan="1">$13.0M to $15.0M</td>
<td colspan="1" rowspan="1">$12.0M to $14.0M</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gross Margin</td>
<td colspan="1" rowspan="1">14% to 17%</td>
<td colspan="1" rowspan="1">14% to 16%</td>
<td colspan="1" rowspan="1">14% to 16%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$0.75M to $1.5M</td>
<td colspan="1" rowspan="1">$0.5M to $1.0M</td>
<td colspan="1" rowspan="1">$0M to $0.5M</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Rockwell Medical Projects Net Sales To Grow In The Mid-to-high Single Digits In 2025 And Beyond, And Gross Margin In 2025 To Be Approximately 20% And Reaching Above 25% In 2026 And Beyond

Rockwell Medical Expects 2024 Sales Of $95.0M-$98.0M Compared To Prior Guidance Of $90.0M-$94.0M And Consensus Of $92.494M

Rockwell Medical Q2 2024 Adj. EPS $0.05 Beats $(0.04) Estimate, Sales $25.800M Beat $22.921M Estimate

Rockwell Medical Announced That It Has Launched A Convenience Pack, Which Includes Two 1-gallon Pre-mixed Containers Of One Of The Company's Hemodialysis Concentrate Products CitraPure, RenalPure, or SteriLyte

Rockwell Medical Raises FY24 Net Sales Outlook To $90.0M-$94.0M Vs. $88.97M Estimate (Prior View: $84.0M-$88.0M);  Projects Net Sales To Grow In The Mid-to-high Single Digits In 2025 And Beyond

Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 80 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $22.68 million which beat the analyst consensus estimate of $21.70 million by 4.50 percent. This is a 15.29 percent increase over sales of $19.67 million the same period last year.

Rockwell Medical Q1 Adj $(0.02) Beats $(0.04) Estimate, Sales $22.68M Beat $21.70M Estimate

<h3>Gainers</h3>
<ul>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. </li>
<li>Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) shares rose 13.5% to $13.7. The market value of their outstanding shares is at $484.7 million. As per the press release, Q1 earnings came out today. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) stock moved upwards by 12.19% to $0.92. The market value of their outstanding shares is at $162.6 million. The company's, Q1 earnings came out today. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) shares moved upwards by 7.77% to $1.94. The market value of their outstanding shares is at $60.1 million. </li>
<li>Gossamer Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOSS#NASDAQ">GOSS</a>) stock moved upwards by 6.94% to $0.77. The market value of their outstanding shares is at $174.1 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) stock moved upwards by 6.43% to $6.48. The company's market cap stands at $69.7 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Augmedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUGX#NASDAQ">AUGX</a>) shares fell 33.8% to $1.55 during Monday's after-market session. The company's market cap stands at $75.8 million. The company's, Q1 earnings came out today. </li>
<li>Akoya Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKYA#NASDAQ">AKYA</a>) stock decreased by 19.91% to $3.3. The market value of their outstanding shares is at $162.9 million. As per the press release, Q1 earnings came out today. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 5.0% to $0.21. The market value of their outstanding shares is at $10.3 million. </li>
<li>Elevation Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELEV#NASDAQ">ELEV</a>) stock declined by 4.81% to $3.37. The company's market cap stands at $184.1 million. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) stock decreased by 4.71% to $1.62. The company's market cap stands at $47.5 million. </li>
<li>Inotiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NOTV#NASDAQ">NOTV</a>) stock declined by 4.08% to $4.0. The market value of their outstanding shares is at $103.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AKYA

AUGX

CLDI

ELEV

GOSS

HROW

LTRN

MODD

NOTV

VXRT

12 Health Care Stocks Moving In Monday's After-Market Session

Rockwell Medical Announced Product Purchase Agreement With US Health Systems In The Mountain West Region To Supply Its Liquid And Dry Acid And Bicarbonate Hemodialysis Concentrates, Cleaning Agents, And Hemodialysis Concentrates Mixers

In the aggregate, these agreements are expected to generate approximately&nbsp;$1 million&nbsp;in annual revenues for the Company.&nbsp;The amended distribution agreement between Rockwell Medical and AMI expands the list of hemodialysis products that AMI is purchasing from the Company, includes purchasing commitments, and generates a profit margin consistent with Rockwell Medical&#39;s gross margin&nbsp;guidance&nbsp;for 2024.

Rockwell Medical Enters New And Expanded Distribution Agreement With BioNuclear And Atlantic Medical International

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and lowers the price target from $11 to $9.

HC Wainwright & Co. Maintains Buy on Rockwell Medical, Lowers Price Target to $9

Rockwell Medical hits 52-week high after supply deal with Nipro

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med (RMTI – Research Report) and keeping the price target at $9.00. ...

Buy Rating Justified by Rockwell Medical's Growth Prospects and Strategic Partnerships

Rockwell Medical enters into product purchase agreement

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med (RMTI – Research Report), with a price targe...

Buy Rating for Rockwell Medical: Growth and Margin Expansion Through Strategic Partnerships and Operational Efficiencies

Rockwell Medical: The Turnaround Is Looking Real

Small-caps get a lift after Fed's jumbo rate cut; see top 20 names per SA Quant ratings

Small-caps get a lift after Fed's jumbo rate cut; see top 20 names in SA Quant ratings

Small-caps get a lift after Fed's jumbo rate cut: See top 20 names in SA Quant ratings

Hedge funds pile into healthcare stocks amid dip, Goldman Sachs says

RMTI files mixed securities shelf

AMSC

AQST

AVDV

AVUV

AXGN

BYRN

CALF

CDNA

CLOV

CRMD

CURI

DAVE

DFAS

DFSV

FNDA

GASS

HMENF

HRTG

IGIC

MESO

NPRRF

PSIX

PSNL

SCHA

SLNCF

USAP

VIRC

Press Releases

Rockwell Medical Announces First Quarter 2024 Results, Raises 2024 Guidance

Rockwell Medical Promotes Tim Chole to Chief Commercial Officer

Rockwell Medical to Release Second Quarter 2024 Results on Thursday, August 8, 2024

Rockwell Medical to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

Rockwell Medical Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities

Rockwell Medical Reports Profitability on a Cash Flow and Adjusted EBITDA Basis in the Second Quarter of 2024

Rockwell Medical Enters into Multi-Million Dollar Distribution Agreement with Nipro Medical Corporation

Rockwell Medical Announces Product Purchase Agreement with Leading At-Home and Acute Care Dialysis Provider

Rockwell Medical Named a Fortune 'Best Workplaces in Manufacturing & Production'

Rockwell Medical to Release Third Quarter 2024 Results on Monday, November 11, 2024

Comments

Rockwell Medical

Vendite allo scoperto

Rockwell Medical (NASDAQ:RMTI) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO